ERBB2 and breast cancer: Additionally, we found that a strong immune status negatively affected the prognosis of HR + /HER2- breast cancer and that immune-related gene signatures should be incorporated into current multi-gene tests to enhance the prognostic value of current molecular subtyping methods.